6/23/2014 7:53:15 AM
DURHAM, N.C., June 23, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the addition of five new directors to its Board. Elected as a new class I director by our stockholders at our 2014 Annual Meeting of Stockholders held on June 20, 2014 was M. Michelle Berrey, M.D., M.P.H., who was named President and CEO of Chimerix in April 2014. Appointed by our Board of Directors to fill vacancies in class II and class III of our Board of Directors were, James M. Daly, Catherine L. Gilliss, Ph.D., R.N., FAAN, John M. Leonard, M.D., and C. Patrick Machado.
Help employers find you! Check out all the jobs and post your resume.
comments powered by